Phase I clinical study of a static magnetic field combined with anti-neoplastic chemotherapy in the treatment of human malignancy: initial safety and toxicity data.
We have completed the lowest level of exposure in a Phase I study, designed to establish the safety and toxicity of the combination of a static magnetic field (SMF) and antineoplastic chemotherapy in patients with advanced malignancy. The SMF application is carefully controlled by applying the magnet to the patient only in our clinic during chemotherapy administration. No increase in the severity of chemotherapy toxicity as measured by white blood cell count and platelet count was seen in the participants exposed to SMF compared to the historical control subjects. These data have permitted the next group of subjects to be treated at the next dose level.
Salvatore
Joseph R
JR
Division of Hematology-Oncology, Carl T Hayden VA Medical Center, Phoenix, Arizona 85012, USA. joseph.salvatore@med.va.gov
Harrington
Joanne
J
Kummet
Thomas
T
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects*; D003131:Combined Modality Therapy / Q000379:methods; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects*; D004307:Dose-Response Relationship, Radiation; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects*; D004574:Electromagnetic Fields / Q000009:adverse effects; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008280:Magnetics / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000628:therapy*; D010976:Platelet Count; D011241:Prednisone / Q000008:administration & dosage* / Q000009:adverse effects*; D011829:Radiation Dosage; D018570:Risk Assessment / Q000379:methods; D018675:Toxicity Tests; D014750:Vincristine / Q000008:administration & dosage* / Q000009:adverse effects*
D000970:Antineoplastic Agents; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone